Glenn Crater, MD

Chief Medical Officer (CMO)
 

Glenn brings more than 20 years of experience in clinical development and medical affairs covering multiple aspects of drug development, including rare diseases. Prior to joining Aro,  Glenn has held executive positions at Inversago Pharma, Theravance Biopharma, Aerocrine and GSK. He has led multiple programs leading to NDA, MAA, and 510K approvals, including products such as  ADVAIR, ANORO, NIOX VERO and YUPELRI. Glenn obtained his MD degree from the University of Tennessee and is Board Certified in Internal Medicine as well as in pulmonary diseases